Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00489970
Status:
COMPLETED
Last Update Posted:
2020-05-01
First Post:
2007-06-21
Brief Title:
Persistence Study of GSK Biologicals Tdap Vaccine 1 3 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap When Administered at Year 9
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline